Effect of Adenovirus-Mediated Heat Shock Protein Expression and Oncolysis in Combination with Low-Dose Cyclophosphamide Treatment on Antitumor Immune Responses
- 15 January 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (2) , 960-969
- https://doi.org/10.1158/0008-5472.can-05-2388
Abstract
Heat shock proteins such as gp96 have the ability to chaperone peptides and activate antigen-presenting cells. In this study, we tested whether adenovirus-mediated overexpression of secreted or membrane-associated forms of gp96 in tumor cells would stimulate an antitumor immune response. Studies were carried out in C57Bl/6 mice bearing aggressively growing s.c. tumors derived from syngeneic TC-1 cells, a cell line that expresses HPV16 E6 and E7 proteins. We found that secreted gp96 can induce protective and therapeutic antitumor immune responses. Our data also indicate that the antitumor effect of sgp96 expression seems to be limited by the induction of suppressive regulatory T cells (Treg). TC-1 tumor transplantation increased the number of splenic and tumor-infiltrating Tregs. Importantly, treatment of mice with low-dose cyclophosphamide decreased the number of Tregs and enhanced the immunostimulatory effect of sgp96 expression. We also tested whether an oncolytic vector (Ad.IR-E1A/TRAIL), that is able to induce tumor cell apoptosis and, potentially, release cryptic tumor epitopes in immunogenic form, could stimulate antitumor immune responses. Although tumor cells infected ex vivo with Ad.IR-E1A/TRAIL had no antitumor effect when used as a vaccine alone, the additional treatment with low-dose cyclophosphamide resulted in the elimination of pre-established tumors. This study gives a rationale for testing approaches that suppress Tregs in combination with oncolytic or immunostimulatory vectors. (Cancer Res 2006; 66(2): 960-9)Keywords
This publication has 47 references indexed in Scilit:
- Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamideBlood, 2005
- Potent Tumor-Specific Immunity Induced by an In vivo Heat Shock Protein-Suicide Gene–Based Tumor VaccineCancer Research, 2004
- Genome Size and Structure Determine Efficiency of Postinternalization Steps and Gene Transfer of Capsid-Modified Adenovirus Vectors in a Cell-Type-Specific MannerJournal of Virology, 2004
- CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curativeEuropean Journal of Immunology, 2004
- A New Type of Adenovirus Vector That Utilizes Homologous Recombination To Achieve Tumor-Specific ReplicationJournal of Virology, 2002
- Toward a New Generation of Conditionally Replicating Adenoviruses: Pairing Tumor Selectivity with Maximal OncolysisHuman Gene Therapy, 2002
- DNA Replication of First-Generation Adenovirus Vectors in Tumor CellsHuman Gene Therapy, 2000
- Heat Shock Protein Expression in Target Cells Infected with Low Levels of Replication-Competent Virus Contributes to the Immunogenicity of Adenoviral VectorsHuman Gene Therapy, 1999
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamideCellular Immunology, 1979